<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sodium phenylbutyrate and taurursodiol (ursodoxicoltaurine): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sodium phenylbutyrate and taurursodiol (ursodoxicoltaurine): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sodium phenylbutyrate and taurursodiol (ursodoxicoltaurine): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="139708" href="/d/html/139708.html" rel="external">see "Sodium phenylbutyrate and taurursodiol (ursodoxicoltaurine): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F57280198"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Relyvrio</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F57165186"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Albrioza</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F57073363"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Histone Deacetylase Inhibitor;</li>
<li>
                        Hydrophilic Bile Acid</li></ul></div>
<div class="block doa drugH1Div" id="F57229545"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1a1f0b9b-307c-4dfa-ad3e-6402def7e3f4">Amyotrophic lateral sclerosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Amyotrophic lateral sclerosis:</b> Initial:<b> Oral:</b> One packet (sodium phenylbutyrate 3 g/taurursodiol 1 g) once daily for 3 weeks, then increase dose to 1 packet twice daily, if tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32877582','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32877582','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F57229547"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate to severe impairment: Avoid use (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F57229548"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate to severe impairment: Avoid use (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F57229546"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F57087353"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (21%), diarrhea (25%), nausea (18%), sialorrhea (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (18%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Nervous system: Dizziness (10%)</p></div>
<div class="block coi drugH1Div" id="F57073362"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to sodium phenylbutyrate, taurursodiol, bile salts, or any component of the formulation; pregnancy; breastfeeding.</p></div>
<div class="block war drugH1Div" id="F57229531"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Biliary disorders: Enterohepatic circulation disorders (eg, biliary infection, active cholecystitis) may increase risk for worsening diarrhea.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pancreatic or intestinal disease: Pancreatic insufficiency (eg, pancreatitis), intestinal malabsorption, or intestinal disorders (eg, ileal resection, regional ileitis) may alter the concentration of bile acids and lead to decreased absorption of sodium phenylbutyrate and taurursodiol.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment due to risk of sodium retention and edema.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Sodium: Use caution in patients sensitive to salt intake (eg, congestive heart failure, hypertension, renal impairment); product contains 928 mg of sodium/2 packets.</p></div>
<div class="block foc drugH1Div" id="F57280199"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Packet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Relyvrio: Sodium phenylbutyrate 3 g and taurursodiol 1 g (7 ea, 56 ea)</p></div>
<div class="block geq drugH1Div" id="F57165184"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F57509861"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Relyvrio Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3-1 g (per each): $276.53</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F57165187"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Packet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Albrioza: Sodium phenylbutyrate 3 g and taurursodiol 1 g (7 ea, 56 ea)</p></div>
<div class="block adm drugH1Div" id="F57229550"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Vigorously stir the contents of 1 packet in a cup (250 mL or 8 oz) of room temperature water. Take before a snack or meal. Administer orally or via feeding tube within 1 hour of preparation; discard unused reconstituted suspension after 1 hour.</p></div>
<div class="block use drugH1Div" id="F57073361"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Amyotrophic lateral sclerosis:</b> Treatment of adults with amyotrophic lateral sclerosis.</p></div>
<div class="block cyt drugH1Div" id="F57149131"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F57149128"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Almagate: May decrease the absorption of Taurursodiol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aluminum Hydroxide: May decrease the absorption of Taurursodiol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors): Taurursodiol may increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May diminish the therapeutic effect of Urea Cycle Disorder Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the absorption of Taurursodiol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BSEP/ABCB11 Inhibitors: May enhance the adverse/toxic effect of Taurursodiol. Specifically, the risk for liver dysfunction may be increased. Management: Avoid coadministration of sodium phenylbutyrate and taurursodiol with BSEP inhibitors when possible. If concomitant use is necessary, monitoring of serum transaminases and bilirubin is recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Corticosteroids (Systemic) may increase protein catabolism and plasma ammonia concentrations, thereby increasing the doses of Urea Cycle Disorder Agents needed to maintain these concentrations in the target range.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inducers): Taurursodiol may decrease the serum concentration of CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inducers). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2B6 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors): Taurursodiol may increase the serum concentration of CYP2B6 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C8 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors): Taurursodiol may increase the serum concentration of CYP2C8 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Taurursodiol. Specifically, the concentrations of phenylbutyrate may be decreased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers): Taurursodiol may decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: May diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Haloperidol may increase plasma ammonia concentrations and thereby increase the doses of Urea Cycle Disorder Agents needed to maintain concentrations in the target range.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Histone Deacetylase Inhibitors: May enhance the adverse/toxic effect of Taurursodiol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OAT1/3 Substrates (Clinically Relevant): Taurursodiol may increase the serum concentration of OAT1/3 Substrates (Clinically Relevant). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors: May increase the serum concentration of Taurursodiol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors): Taurursodiol may increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase serum concentrations of the active metabolite(s) of Urea Cycle Disorder Agents. Specifically, concentrations of phenylacetate and phenylacetylglutamine may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: Histone Deacetylase Inhibitors may enhance the adverse/toxic effect of Taurursodiol. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F57229529"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were observed in some animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F57229530"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if sodium phenylbutyrate, taurursodiol, or their metabolites are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F57229549"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Administer before a snack or meal. Product contains dextrates, sodium, sorbitol, and sucralose.</p></div>
<div class="block pha drugH1Div" id="F57229535"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">The mechanism by which the decline of physical function is decreased in patients with amyotrophic lateral sclerosis is unknown. The combination of sodium phenylbutyrate and taurursodiol reduces neuronal cell death in vitro.</p></div>
<div class="block phk drugH1Div" id="F57229536"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Sodium phenylbutyrate: Rapid; administration with a high-fat meal results in C<sub>max</sub> decreased by 76% and AUC decreased by 54%.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Sodium phenylbutyrate: 82%; taurursodiol: 98%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic (saturable); sodium phenylbutyrate is metabolized by β-oxidation in the liver and kidney to phenylacetate, which is rapidly conjugated with glutamine via acetylation to form phenylacetylglutamine; taurursodiol undergoes enterohepatic recirculation and is deconjugated to ursodeoxycholic acid (UDCA) by intestinal microflora, which is reconjugated in the liver with glycine or taurine (glycoursodeoxycholic acid [GUDCA] and taurursodiol, respectively).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Phenylbutyrate: 0.46 hours; phenylacetate: 0.81 hours; taurursodiol: 4.34 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Median: Phenylbutyrate: 0.5 hours; taurursodiol: 4.5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~80% to 100% as phenylacetylglutamine [metabolite of sodium phenylbutyrate]).</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Albrioza.1">
<a name="Albrioza.1"></a>Albrioza (sodium phenylbutyrate and taurursodiol) [product monograph]. Milton, Ontario, Canada: Innomar Strategies; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32877582">
<a name="32877582"></a>Paganoni S, Macklin EA, Hendrix S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. <i>N Engl J Med</i>. 2020;383(10):919-930. doi:10.1056/NEJMoa1916945<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-phenylbutyrate-and-taurursodiol-ursodoxicoltaurine-drug-information/abstract-text/32877582/pubmed" id="32877582" target="_blank">32877582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32877582">
<a name="32877582"></a>Relyvrio (sodium phenylbutyrate and taurursodiol) [prescribing information]. Cambridge, MA: Amylyx Pharmaceuticals Inc; September 2022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-phenylbutyrate-and-taurursodiol-ursodoxicoltaurine-drug-information/abstract-text/32877582/pubmed" id="32877582" target="_blank">32877582</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 139291 Version 28.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
